Expert Interview
Discussing Incyte Corporation's Opzelura Cream (Ruxolitinib) in Atopic dermatitis, following recent FDA Approval
Ticker(s): INCYA dermatologist with experience in treating Atopic dermatitis
Please tell us about your clinical experience. How many patients with atopic dermatitis do you see on a yearly basis? What is the standard of care, and how do you think Incyte's opzelura will fit in the space?
Could you tell us more about the mechanism of action of Janus kinase (JAK) inhibitors, and how it relates to treating atopic dermatitis?
Added By: catalin_adminHow significant are the results of reduced the skin inflammation and itch associated with AD (reduction in itch from baseline at Week 8, on itch NRS4: 52.2% in TRuE-AD1 and 50.7% in TRuE-AD2, compared to vehicle (15.4% in TRuE-AD1, 16.3% in TRuE-AD2, among patients with an NRS score of at least 4 at baseline). Do you see this being translated into meaningful positive outcomes for your patients?
Added By: catalin_adminCould you also comment on the primary endpoint of 53.8% in TRuE-AD1 and 51.3% in TRuE-AD2, compared to vehicle (15.1% in TRuE-AD1, 7.6% in TRuE-AD2), how well do you think these results will show into real world efficacy for your patients?
Added By: catalin_adminHow big is the need for new drugs in treating atopic dermatitis?
How likely are you to consider prescribing Opzelura Cream for your patients?
Added By: catalin_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
